Please assess the completion status of the following clinical trial:

Trial Title: Tritanium® Primary Acetabular Shell Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A. Patient has signed an IRB approved, study specific Informed Patient Consent Form.~* B. Patient is a male or non-pregnant female age 18 years or older at time of study device implantation.~* C. Patient has primary diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD).~* D. Patient is a candidate for a primary cementless total hip replacement.~* E. Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.~Exclusion Criteria:~* F. Patient has a Body Mass Index (BMI) ≥ 40.~* G. Patient has an active or suspected latent infection in or about the affected hip joint at time of study device implantation.~* H. Patient has a neuromuscular or neurosensory deficiency, which limits the ability to evaluate the safety and efficacy of the device.~* I. Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's Disease) leading to progressive bone deterioration.~* J. Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. \> 30 days).~* K. Patient requires revision surgery of a previously implanted total hip replacement or hip fusion to the affected joint.~* L. Patient has a known sensitivity to device materials.~* M. Patient is a prisoner.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tritanium® Primary Acetabular Shell (Type: OTHER): Tritanium® Primary Acetabular Shell

Based on this trial design, predict the completion outcome and termination type (if applicable).